glyceryl-2-arachidonate has been researched along with Fragile-X-Syndrome* in 2 studies
2 other study(ies) available for glyceryl-2-arachidonate and Fragile-X-Syndrome
Article | Year |
---|---|
Treating a novel plasticity defect rescues episodic memory in Fragile X model mice.
Episodic memory, a fundamental component of human cognition, is significantly impaired in autism. We believe we report the first evidence for this problem in the Fmr1-knockout (KO) mouse model of Fragile X syndrome and describe potentially treatable underlying causes. The hippocampus is critical for the formation and use of episodes, with semantic (cue identity) information relayed to the structure via the lateral perforant path (LPP). The unusual form of synaptic plasticity expressed by the LPP (lppLTP) was profoundly impaired in Fmr1-KOs relative to wild-type mice. Two factors contributed to this defect: (i) reduced GluN1 subunit levels in synaptic NMDA receptors and related currents, and (ii) impaired retrograde synaptic signaling by the endocannabinoid 2-arachidonoylglycerol (2-AG). Studies using a novel serial cue paradigm showed that episodic encoding is dependent on both the LPP and the endocannabinoid receptor CB Topics: Animals; Arachidonic Acids; Discrimination, Psychological; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fragile X Syndrome; Glycerides; Hippocampus; Long-Term Potentiation; Male; Memory, Episodic; Mice, Knockout; Nerve Tissue Proteins; Neurotransmitter Agents; Olfactory Perception; Patch-Clamp Techniques; Receptor, Cannabinoid, CB1; Receptors, N-Methyl-D-Aspartate; Tissue Culture Techniques | 2018 |
Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.
Fragile X syndrome, the most commonly known genetic cause of autism, is due to loss of the fragile X mental retardation protein, which regulates signal transduction at metabotropic glutamate receptor-5 in the brain. Fragile X mental retardation protein deletion in mice enhances metabotropic glutamate receptor-5-dependent long-term depression in the hippocampus and cerebellum. Here we show that a distinct type of metabotropic glutamate receptor-5-dependent long-term depression at excitatory synapses of the ventral striatum and prefrontal cortex, which is mediated by the endocannabinoid 2-arachidonoyl-sn-glycerol, is absent in fragile X mental retardation protein-null mice. In these mutants, the macromolecular complex that links metabotropic glutamate receptor-5 to the 2-arachidonoyl-sn-glycerol-producing enzyme, diacylglycerol lipase-α (endocannabinoid signalosome), is disrupted and metabotropic glutamate receptor-5-dependent 2-arachidonoyl-sn-glycerol formation is compromised. These changes are accompanied by impaired endocannabinoid-dependent long-term depression. Pharmacological enhancement of 2-arachidonoyl-sn-glycerol signalling normalizes this synaptic defect and corrects behavioural abnormalities in fragile X mental retardation protein-deficient mice. The results identify the endocannabinoid signalosome as a molecular substrate for fragile X syndrome, which might be targeted by therapy. Topics: Animals; Arachidonic Acids; Endocannabinoids; Fragile X Mental Retardation Protein; Fragile X Syndrome; Glycerides; Lipoprotein Lipase; Male; Mice; Mice, Knockout; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Signal Transduction | 2012 |